Lipid-lowering therapy after coronary artery bypass surgery: The Post-CABG trial

Cleveland Clinic Journal of Medicine

Volumn 64, Issue 7, 1997, Pages 347-351

  Stewart, William J ^a   Hoogwerf, Byron J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; MEVINOLIN; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL PROTOCOL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; POSTOPERATIVE PERIOD; REVIEW; TREATMENT PLANNING;

EID: 0030854001     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.64.7.347     Document Type: Article

References (24)

1. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336:153-162.
2. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
3. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351-364.
4. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365-374.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994; 344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
8. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323:1289-1298.
9. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary arteriosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012.
10. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet or diet plus cholestyramine in the St. Thomas' atherosclerosis regression study (STARS). Lancet 1992; 339:563-569.
11. Blankenhom DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Ann Intern Med 1993: 119:969-976.
12. Waters D, Higginson L, Gladstone P, et al. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian coronary atherosclerosis intervention trial. Circulation 1994: 89:959-968.
13. Haskell WL, Adelman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford coronary risk intervention project (SCRIP). Circulation 1994; 89:975-990.
14. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre antiatheroma study (MAAS). Lancet 1994; 344:633-638.
15. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26:1133-1139.
16. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-2540.
17. Lie JT, Lawrie GM, Morris GC. Aortocoronary bypass saphenous vein graft atherosclerosis. Anatomic study of 99 grafts from normal and hyperlipoproteinemic patients up to 75 months postoperatively. Am J Cardiol 1977; 40:906-914.
18. Neitzel GF, Barhoriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986; 6:594-600.
19. Palac RT, Meadows WR, Hwang MH, Loeb HS, Pifarre R, Gunnar RM. Risk factors related to progressive narrowing in aortocoronary vein grafts studied 1 to 5 years after surgery. Circulation 1982; 66:40-44.
20. Campeau L, Enjalbert M, Lespérance J, et al. The relation of risk factors to the development of arteriosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-1332.
21. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to rick factors. Circulation 1988; 78(Suppl I):I-140-143.
22. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, and Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233-3240.
23. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89:1329-1445.
24. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D. An application of the Zucker-Wittes modified ratio estimate statistic in the POST-CABG clinical trial. Controlled Clinical Trials. In press.